WO2008077592A1 - Method for purifying rna on a preparative scale by means of hplc - Google Patents
Method for purifying rna on a preparative scale by means of hplc Download PDFInfo
- Publication number
- WO2008077592A1 WO2008077592A1 PCT/EP2007/011294 EP2007011294W WO2008077592A1 WO 2008077592 A1 WO2008077592 A1 WO 2008077592A1 EP 2007011294 W EP2007011294 W EP 2007011294W WO 2008077592 A1 WO2008077592 A1 WO 2008077592A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- separation
- porous
- vol
- hplc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- the present invention relates to a method for purifying RNA on a preparative scale by means of HPLC and to the use of a porous reversed phase as stationary phase in this method.
- HPLC abbreviation for "High Performance (High Pressure) Liquid Chromatography” is an established method of separating mixtures of substances, which is widely used in biochemistry, analytical chemistry and clinical chemistry.
- An HPLC apparatus consists in the simplest case of a pump with eluent reservoir containing the mobile phase, a sample application system, a separation column containing the station- ary phase, and the detector.
- a fraction collector may also be provided, with which the individual fractions may be separately collected after separation and are thus available for further applications.
- RNA analysis using ion pair reversed phase HPLC is known from A. Azarani and K. H. Hecker (Nucleic Acids Research, vol. 29, no. 2 e7).
- the stationary phase here consists of a non-porous alkylated polystyrenedivinylbenzene matrix. Elution proceeds with a buffer system of two eluents.
- Buffer A consists of an aqueous solution of 0.1 M triethylammonium acetate (TEAA), pH 7.0
- buffer B consists of an aqueous solution of 0.1 M TEAA, pH 7.0, with 25% acetonitrile.
- Elution was performed using the following three gradient sys- terns: 38-40% B over 1 minute, to 60% B over 15 minutes, to 66% B over 6 minutes, to 70% B over 0.5 minutes, to 100% B over 0.5 minute, holding at 100% B for 1 minute, to 38% over 1 minute, holding at 38% B for 2 minutes.
- the following gradient program was used: 38-60% over 30 minutes, to 100% B over 2 minutes, to 38% B over 3 minutes.
- the following was used as a third gradient program: 38-40% B over 1 minute, to 60% B over 3 minutes, to 100% B over 1 minute, holding at 100% B over 6 minutes, to 38% B over 1 minute, holding at 38% B over 1 minute.
- the object of the present invention is here to improve a method of this type to the effect that it no longer exhibits the disadvantages of the prior art.
- RNA is purified by means of HPLC using a porous reversed phase as stationary phase.
- a porous reversed phase is used.
- HPLC by means of HPLC
- HPLC various HPLC methods as well as low or normal pressure liquid chromatography methods, which may be used to carry out the inventive method.
- HPLC reversed phase HPLC
- chromatography size exclusion chromatography
- gel filtration gel filtration
- affinity chroma- tography gel filtration
- hydrophobic interaction chromatography hydrophobic interaction chromatography or ion pair chromatography
- reversed phase HPLC consists of a non-polar stationary phase and a moderately polar mobile phase.
- One common stationary phase is e.g. a silica which has been treated with e.g.
- RMe 2 SiCI where R is a straight chain alkyl group such as C 18 H 37 or C 8 H 17 .
- the retention time is therefore longer for mole- cules which are more non-polar in nature, allowing polar molecules to elute more readily. Retention time is increased by the addition of polar solvent to the mobile phase and decreased by the addition of more hydrophobic solvent.
- the various techniques mentioned above operate on the principle of hydrophobic interactions which result from repulsive forces between a relatively polar solvent, the relatively non-polar analyte, and the non-polar stationary phase (reversed phase principle).
- the driving force in the binding of the analyte (the RNA molecule) to the stationary phase is the decrease in the area of the non-polar segment of the analyte molecule exposed to the sol- vent.
- This hydrophobic effect is dominated by the decrease in free energy from entropy associated with the minimization of the ordered molecule-polar solvent interface.
- the hydrophobic effect is decreased by adding more non-polar solvent into the mobile phase. This shifts the partition coefficient such that the analyte spends some portion of time moving down the column in the mobile phase, eventually eluting from the column.
- RNA molecule as an analyte may play an important role in its retention characteristics.
- an analyte having more apolar functional groups results in a longer retention time because it increases the molecule's hydrophobicity.
- Very large molecules can result in incomplete interaction between the large analyte surface and the alkyl chain. Retention time increases with hydrophobic surface area which is roughly inversely proportional to solute size. Branched chain compounds elute more rapidly than their corresponding isomers because the overall surface area is decreased.
- RNA molecule retention Aside from mobile phase hydrophobicity, other mobile phase modifiers can - according to the invention - affect analyte (RNA molecule) retention.
- the addition of inorganic salts may be considered to cause a linear increase in the surface tension of aqueous solutions, and because the entropy of the analyte-solvent interface is controlled by surface tension, the addition of salts tend to increase the retention time.
- Another important compo- nent, which may be used according to the invention is pH, since this can change the hydrophobicity of the analyte. For this reason, a buffering agent, such as sodium phosphate or other common buffering agents, may be used to control the pH.
- An organic acid such as formic acid or most commonly trifluoroacetic acid, may be added to mobile phase.
- the above modifications may serve multiple purposes: They control pH, neutralize the charge on any residual exposed material on the stationary phase and act as ion pairing agents to neutralize charge on the analyte. The effect varies depending on use but generally improve the chromatography.
- the term "purification" is understood to mean that the desired RNA in a sample is separated and/or isolated from the impurities present therein.
- the RNA is present in a purer form than in the originally introduced RNA-containing sample prior to HPLC purification.
- Undesired constituents of RNA- containing samples which therefore need to be separated may in particular be degraded fragments or fragments which have arisen as a result of premature termination of transcription, or also excessively long transcripts if plasmids are not completely linearised.
- impurities such as enzymes, for example RNases and polymerases, and nucleotides may be separated.
- RNA is purified which has a higher purity after purification than the starting material. It is desirable in this respect for the degree of purity to be as close as possible to 100%. A degree of purity of more than 70%, in particular 80%, very particularly 90% and most favourably 99% or more may be achieved in this way.
- the method according to the invention results in preparative RNA purification.
- an analytical HPLC method a distinctly smaller quantity is introduced and separated than in a preparative HPLC method.
- quanti- ties of 8 ng to 1000 ng were introduced.
- a preparative HPLC method should be understood to mean an HPLC method in which relatively large quantities of RNA are purified.
- Such relatively large quantities are for example quantities of 0.5 mg or more, in particular 1 .0 mg to 1000 mg or more, very particularly approximately 1.5 mg or more, upscal- ing even to the kg range being possible.
- the above statements are therefore to be under- stood to mean that these quantities relate to a single HPLC run. If a plurality of HPLC runs are performed, the quantity increases in direct proportion to the number of HPLC runs.
- the method according to the invention exhibits a series of advantages: using the method according to the in- vention substantially larger quantities of RNA may be separated than is possible with the method known from the prior art. Using the method according to the invention, these relatively high quantities are obtained with a high degree of purity. Separation of degraded fragments or excessively long fragments or of fragments which have arisen as a result of premature termination of transcription is possible. In addition, good separation of further impurities present in RNA samples, such as enzymes, for example RNases and polymerases, and nucleotides is possible. These relatively large quantities of RNA may be recovered within minutes, even from samples having a very high level of contamination with impurities.
- RNA recovery proceeds reliably, i.e. high purity RNA is recovered with great reliability.
- a high level of resolution may be achieved.
- the method according to the invention may additionally easily be operated automatically. It is thus most suitable for routine purification of RNA on a preparative scale.
- RNA is stable under the conditions of the method according to the invention, i.e. degradation during HPLC purification into RNA fragments and thus the occurrence of new impurities and a reduction in the yield of desired RNA during HPLC purification is avoided.
- the method according to the invention may thus be performed in a simple, rapid, inexpensive manner, accurately and with reliable results. Isolation of RNA after HPLC separation may proceed simply with a fraction collector, i.e. the recovery of RNA may be achieved very simply, it being possible for direct further processing of the RNA likewise to take place. Detection may finally be performed very sensitively.
- RNA which is to be purified with the method according to the invention is ribonucleic acid of any type.
- the RNA is particularly preferably selected from tRNA, rRNA, mRNA or whole-cell RNA.
- the RNA may also comprise aptamers and ribozymes.
- the RNA to be isolated may be single-stranded or double-stranded. Single-stranded RNA may optionally form secondary structures by refolding, the RNA to be separated typically being single-stranded.
- the RNA may be unlabelled or also labelled (with a fluorescent label or a radiolabel or an antibody epitope).
- a labelled RNA is digoxigenin-labelled ⁇ -actin RNA.
- the RNA to be purified may be native or non-native RNA.
- Native RNA is preferably used, which is prepared using a for example cellular or in vitro expression system.
- the RNA is then isolated and the isolate purified using the method according to the invention.
- chemically synthesised RNA may also be purified using the method according to the invention.
- the RNA may also contain non-native nucleotides, wherein the chemical modifications may be present in the backbone of the RNA, for example phosphor- thioate, in the structure of the nucleotide base, for example hypoxanthine, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C1 -C6)-alkyluracil, 5-(C2-C6)- alkenyluracil, 5-(C2-C6)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5- fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C1 -C6)-alkylcytosine, 5-(C2-C6)- alkenylcytosine, 5-(C2-C6)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5- bromocytosine, N ⁇ 2
- modified nucleotides are 2-amino-6-chloropurine-riboside-5'-triphosphate, 2-aminoadenosine-5 '-triphosphate, 2-thiocytidine-5 '-triphosphate, 2-thiouridine-5'- triphosphate, 4-thiouridine-5'-triphosphate, 5-aminoallylcytidine-5'-triphosphate, 5- aminoallyluridine-5'-triphosphate, 5-bromocytidine-5'-triphosphate, 5-bromouridine-5'- triphosphate, 5-iodocytidine-5 '-triphosphate, 5-iodouridine-5'-triphosphate, 5- methylcytidine-5 '-triphosphate, 5-methyluridine-5 '-triphosphate, 6-azacytidine-5'- triphosphate, 6-azauridine-5 '-triphosphate, 6-chloropurine-riboside-5'-triphosphate, 7- deazaadenosine-5 '-triphosphat
- the RNA to be separated has a size of up to about 15000 nucleotides (as single stranded RNA molecule) or base pairs (as double stranded RNA molecule), in particular 100 to 10000, more preferably 500 to 10000 nucleotides or base pairs, even more preferably 800 to 5000 nucleotides or base pairs and even more preferably 800 to 2000 nucleotides or base pairs.
- this size of RNA it has proved possible to achieve very good results with regard to purification of the RNA, since the method according to the invention is particularly well suited to RNA of this size.
- smaller RNA fragments for example with a length of 30-1000, 50- 1000 or 100-1000 or 20-200, 20-100, 20-50 or 20-30 nucleotides may also be separated in this way.
- RNA to be separated is mRNA
- this will preferably code for proteins, in particular those which have an antigen character, and for example all recombinantly produced or naturally occurring proteins, which are known to a person skilled in the art from the prior art and are used for therapeutic, diagnostic or research purposes.
- the antigens are then tumour antigens or antigens of pathogens, for example viral, bacterial or protozoal organisms.
- proteins include inter alia growth hormones or growth factors, for example for promoting growth in a (transgenic) living organism such as for example TGF and the IGFs ("insulin-like growth factors"), proteins which influence metabolism and/or haematopoiesis, such as for example (alpha-l )-anti-trypsin, LDL receptor, erythropoietin (EPO), insulin, GAT A-1 , etc., or proteins such as for example factors VIII and Xl of the blood clotting system, etc..
- Such proteins further include enzymes, such as for example
- proteases such as for example papain, bromelain, keratinases, trypsin, chymotrypsin, pepsin, rennin (chymosin), suizyme, nortase, etc., and protease inhibitors (for example for the treatment of HIV infections), such as for example protease inhibitors se- lected from a group consisting of AG1 776, amprenavir (141W94 or VX-478), atazanavir (BMS-232632), cathepsin S protease inhibitor, D1927, D9120, fosamprenavir (GW-433908 or VX-175), GS 9005, GW640385 (VX-385), HCV protease inhibitor, indinavir (MK-639), L- 756 423
- the proteins coded from the RNA separated according to the invention may likewise comprise proteins which stimulate or inhibit cell signal transmission, for example cytokines, etc.. Such proteins therefore also comprise for example cytokines of class I of the cytokine family, which comprise 4 posi- tionally conserved cysteine residues (CCCC) and one conserved sequence motif Trp-Ser-X- Trp-Ser (WSXWS), wherein X represents a non-conserved amino acid.
- cytokines of class I of the cytokine family which comprise 4 posi- tionally conserved cysteine residues (CCCC) and one conserved sequence motif Trp-Ser-X- Trp-Ser (WSXWS), wherein X represents a non-conserved amino acid.
- Cytokines of class I of the cytokine family comprise the GM-CSF subfamily, for example IL-3, IL-5, GM-CSF, the IL-6 subfamily, for example IL-6, IL-1 1 , IL-12, or the IL-2 subfamily, for example IL-2, IL-4, IL-7, IL-9, IL-15, etc., or the cytokines IL-I , IL- 1 , IL-10 etc..
- such proteins may also comprise cytokines of the class Il of the cytokine family (interferon receptor family), which likewise comprise 4 positionally conserved cysteine residues (CCCC), but no conserved sequence motif Trp-Ser-X-Trp-Ser (WSXWS).
- Cytokines of class Il of the cytokine family include for example IFN-alpha, IFN-beta, IFN-gamma, etc..
- the proteins coded by the separated RNA may furthermore also include cytokines of the tumour necrosis family including for example TNF-alpha, TNF-beta, CD40 ligand, Fas ligand, etc., or cytokines of the chemokine family, in particular interferons, interleukins, colony-stimulating factors and tumour necrosis factors, and interact with G protein, for example IL-8, MIP-1 , RANTES, CCR5, CXR4, etc.
- Such proteins may also be selected from apoptosis factors or apoptosis- related or -linked proteins, including AIF, Apaf, for example Apaf-1 , Apaf-2, Apaf-3, or APO-2 (L), APO-3 (L), apopain, Bad, Bak, Bax, Bcl-2, Bcl-x L , Bcl-x s , bik, CAD, calpain, cas- pases for example caspase-1 , caspase-2, caspase-3, caspase-4, caspase-5, caspase-6, cas- pase-7, caspase-8, caspase-9, caspase-10, caspase-1 1 , ced-3, ced-9, c-Jun, c-Myc, crm A, cytochrome C, CdR1, DcRI , DD, DED, DISC, DNA-PKc 5 , DR3, DR4, DR5, FADD/MORT-1 , FA
- the proteins coded by RNA separated according to the invention may also be selected from antigens, for example from tumour-specific surface antigens (TSSA), for example 5T4alpha5 betai integrin, 707-AP, AFP, ART-4, B7H4, BAGE, Bcr-abl, MN/C IX-antigen, CAI 25, CAMEL, CAP-1 , CASP-8, beta-catenin/m, CD4, CD19, CD20, CD22, CD25, CDC27/m, CD30, CD33, CD52, CD56, CD80, CDK4/m, CEA, CT, Cyp-B, DAM, EGFR, ErbB3, ELF2M, EMMPRIN, EpCam, ETV6-AML1 , G250, GAGE, GnT-V, Gp100, HAGE, HER-2/new, HLA-A*0201 - R170I, HPV-E7, HSP70-2M, HAST-2, hTERT (or
- Proteins which may be coded by the RNA separated according to the invention additionally also include proteins or protein sequences which exhibit sequence identity of at least 80% or 85%, preferably at least 90%, more preferably at least 95% and most preferably at least 99% to one of the above-described proteins.
- the mRNA to be separated may exhibit the following modifications relative to a corresponding wild-type mRNA, which may either be present as alternatives or in combination.
- the G/C content of the region of the modified mRNA coding for a peptide or polypeptide may be greater than the G/C content of the coding region of the wild-type mRNA coding for the peptide or polypeptide, the coded amino acid sequence being unchanged relative to the wild-type.
- This modification is based on the fact that the sequence order of the mRNA domain to be translated is essential for efficient mRNA translation. In this respect, the composition and sequence of the various nucleotides has an important part to play.
- sequences with an elevated G(guanosine)/C(cytosine) content are more stable than sequences with an elevated A(adenosine)/U(uracil) content.
- the codons are varied relative to the wild-type mRNA in such a manner that they have a greater content of G/C nucleotides. Since several codons code for one and the same amino acid (degeneration of the genetic code), it is possible to determine the codons which are most favourable for stability (alternative codon usage). On the other hand it is also possible to provide a translation-optimised RNA with the method according to the invention.
- a reversed phase is used as the stationary phase for HPLC purification.
- a nonpolar compound serves as the stationary phases and a polar solvent, such as mixtures of water, which is generally used in the form of buffers, with e.g. acetonitrile and/or methanol, serves as the mo- bile phase for elution.
- the material packed on the column which is used as stationary phase, may be provided in bead form or as a polymerized "block", i.e. a block which fills a substantial part of the chromatography column.
- the polymeric stationary phase is porous in its nature, which means that the beads or the block are characterized by pores.
- the porous reversed phase material is provided with a particle size of 8.0 ⁇ m to 50 ⁇ m, in particular 8.0 to 30, still more preferably 8.0 to 25 ⁇ m.
- the reversed phase material may be present in the form of small spheres.
- the method according to the invention may be performed particularly favourably with a porous reversed phase with this particle size, optionally in bead form, wherein particularly good separation results are obtained.
- the reversed phase used in the method according to the invention is porous and has specific particle sizes. With stationary reversed phases which are not porous and thus differ completely with regard to particle size from the subject matter of the present invention as described for example by A. Azarani and K.H. Hecker, on the other hand, excessively high pressures are built up, such that preparative purification of the RNA is possible only with great difficulty, if at all.
- the reversed phase has a pore size of 1000 ⁇ to 5000 A, in particular a pore size of 1000 A to 4000 A, more pref- erably 1500 A to 4000 A, 2000 A to 4000 A or 2500 A to 4000 A.
- Particularly preferred pore sizes for the reversed phases are 1000 A to 2000 A, more preferably 1000 A to 1500 A and most preferably 1000 A to 1200 A or 3500-4500 A.
- a pore size of 1000 A to 5000 A, in particular a pore size of 1000 A to 4000 A, more pref- erably 1500 A to 4000 A, 2000 A to 4000 A or 2500 A to 4000 A may be suitable to separate a RNA from other components of a mixture, the RNA having a size as mentioned above of up to about 15000 nucleotides (as single stranded RNA molecule) or base pairs (as double stranded RNA molecule), in particular 100 to 10000, more preferably 500 to 10000 nucleotides or base pairs, even more preferably 800 to 5000 nucleotides or base pairs and even more preferably 800 to 2000 nucleotides or base pairs.
- the pore size of the reversed phase may also be selected in dependence of the size of the RNA to be separated, i.e. a larger pore size may be selected, if larger RNA molecules are to be separated and smaller pore sizes may be selected, if smaller RNA molecules may be selected.
- a larger pore size may be selected, if larger RNA molecules are to be separated and smaller pore sizes may be selected, if smaller RNA molecules may be selected.
- a pore size for the reversed phase of about 2000 A to about 5000 A, more preferably of about 2500 to about 4000, most preferably of about 3500 to about 4500 A may thus be used to separate larger RNA molecules, e.g. RNA molecules of 100 to 10000, more preferably 500 to 10000 nucleotides or base pairs, even more preferably 800 to 5000 nucleotides or base pairs and even more preferably 800 to 2000 nucleotides or base pairs.
- a pore size of for the reversed phases of about 1000 ⁇ to about 2500 A, more preferably of about 1000 A to about 2000 A, and most preferably of about 1000 A to 1200 A may be used to separate smaller RNA molecules, e.g. RNA molecules of about 30-1000, 50-1000 or 100-1000 or 20-200, 20-100, 20-50 or 20- 30 nucleotides may also be separated in this way.
- any material known to be used as reverse phase stationary phase in particular any polymeric material may be used for the inventive method, if that material can be provided in porous form.
- the stationary phase may be composed of organic and/or inorganic material.
- polymers to be used for the present invention are (non-alky lated) polystyrenes, (non-alkylated) polystyrenedivinylbenzenes, silica gel, silica gel modified with non-polar residues, particularly silica gel modified with alkyl containing residues, more preferably with butyl-, octyl and/or octadecyl containing residues, silica gel modified with phenyl ic residues, polymethacrylates, etc..
- dextran including e.g. Sephadex ® and Sephacryl ® materials, agarose, dextran/agarose mixtures, poly- acrylamide, etc..
- dextran including e.g. Sephadex ® and Sephacryl ® materials, agarose, dextran/agarose mixtures, poly- acrylamide, etc.
- the material for the reversed phase is a porous polystyrene polymer, a (non-alkylated) (porous) polystyrenedivinylbenzene polymer, porous silica gel, porous silica gel modified with non-polar residues, particularly porous silica gel modified with alkyl containing residues, more preferably with butyl-, octyl and/or octadecyl containing residues, porous silica gel modified with phenylic residues, porous polymethacrylates, wherein in particular a porous polystyrene polymer or a non-alkylated (porous) polystyrenedivinylbenzene may be used.
- a non-alkylated porous polystyrenedivinylbenzene which is very particularly preferred for the method according to the invention is one which, without being limited thereto, may have in particular a particle size of 8.0 ⁇ 1.5 ⁇ m, in particular 8.0 ⁇ 0.5 ⁇ m, and a pore size of 1000- 1500 A, in particular 1000-1200 A or 3500-4500 A.
- This stationary phase described in greater detail above is conventionally located in a column.
- V2A steel is conventionally used as the material for the column, but other materials may also be used for the column provided they are suitable for the conditions prevailing during HPLC.
- the column is straight. It is favourable for the HPLC column to have a length of 5 cm to 100 cm and a diameter of 4 mm to 25 mm.
- Columns used for the method according to the invention may in particular have the following dimensions: 50 mm long and 7.5 mm in diameter or 50 mm long and 4.6 mm in diameter, or 50 mm long and 10 mm in diameter or any other dimension with regard to length and diameter, which is suitable for preparative recovery of RNA, even lengths of several metres and also larger diameters being feasible in the case of upscaling.
- the dimensions are here geared towards what is technically possible with liquid chromatography.
- the method according to the invention is performed as an ion pair method, wherein an ion with a lipophilic residue and positive charge is added to the mobile phase as counterion for the negatively charged RNA.
- an ion pair with lipophilic character is obtained, which is slowed down by the nonpolar stationary phase of the reversed phase system.
- the precise conditions for the ion pair method have to be empirically worked out for each specific separation problem.
- the size of the counterion, its concentration and the pH value of the solution contribute greatly to the separation result. This means that the empirically established conditions of an ion pair method cannot be straightforwardly applied to a different separation problem.
- Alkylammo- nium salts such as triethylammonium acetate, and/or tetraalkylammonium compounds, such as tetrabutylammonium, are favourably added in the method according to the inven- tion.
- 0.1 M triethylammonium acetate is added and the pH value is adjusted to about 7.
- RNA on a preparative scale, in a particularly favourable manner.
- the following may be considered as further buffer solutions: trifluoroace- tic acid, acetic acid, formic acid, acetate buffer, phosphate buffer, tetrabutylammonium bisulfate, tetrabutylammonium bromide and tetrabutylammonium chloride.
- Selection of the mobile phase depends on the type of separation desired. This means that the mobile phase established for a specific separation, as may be known for example from the prior art, cannot be straightforwardly applied to a different separation problem with a sufficient prospect of success. For each separation problem, the ideal elution conditions, in particular the mobile phase used, have to be determined by empirical testing.
- a mixture of an aqueous solvent and an organic solvent is used as the mobile phase for eluting the RNA.
- a buffer to be used as the aqueous solvent which has in particular a pH of 6.0-8.0, for example of about 7, for example. 7.0; preferably the buffer is triethylammonium acetate, particularly preferably a 0.02 M to 0.5 M, in particular 0.08 M to 0.12 M, very particularly an about 0.1 M triethylammonium acetate buffer, which, as described above, also acts as a counterion to the RNA in the ion pair method.
- the organic solvent which is used in the mobile phase is ace- tonitrile, methanol, ethanol, 1 -propanol, 2-propanol and acetone or a mixture thereof, very particularly preferably acetonitrile.
- the mobile phase is a mixture of 0.1 M triethylammonium acetate, pH 7, and acetonitrile.
- the mobile phase it has proven particularly favourable for the method according to the invention for the mobile phase to contain 5.0 vol.% to 25.0 vol.% organic solvent, relative to the mobile phase, and for this to be made up to 100 vol.% with the aqueous solvent.
- the proportion of organic solvent is increased, in particular by at least 10%, more preferably by at least 50% and most preferably by at least 100%, optionally by at least 200%, relative to the initial vol.% in the mobile phase.
- the proportion of organic solvent in the mobile phase amounts in the course of HPLC separation to 3 to 9, preferably 4 to 7.5, in particular 5.0 vol.%, in each case relative to the mobile phase.
- the proportion of organic solvent in the mobile phase is increased in the course of HPLC separation from 3 to 9, in particular 5.0 vol.% to up to 20.0 vol.%, in each case relative to the mobile phase. Still more preferably, the method is performed in such a way that the proportion of organic sol- vent in the mobile phase is increased in the course of HPLC separation from 6.5 to 8.5, in particular 7.5 vol.%, to up to 1 7.5 vol.%, in each case relative to the mobile phase.
- the mobile phase contains 7.5 vol.% to 17.5 vol.% organic solvent, relative to the mo- bile phase, and for this to be made up to 100 vol.% with the aqueous buffered solvent.
- elution may proceed isocratically or by means of gradient separation.
- elution of the RNA proceeds with a single eluent or a constant mixture of a plurality of eluents, wherein the solvents described above in detail may be used as eluent.
- gradient separation is performed.
- the composition of the eluent is varied by means of a gradient program.
- the equipment necessary for gradient separation is known to a person skilled in the art.
- Gradient elution may here proceed either on the low pressure side by mixing chambers or on the high pressure side by further pumps.
- the proportion of organic solvent, as described above, is increased relative to the aqueous solvent during gradient separation.
- the above-described agents may here be used as the aqueous solvent and the likewise above-described agents may be used as the organic solvent.
- the proportion of organic solvent in the mobile phase may be increased in the course of HPLC separation from 5.0 vol.% to 20.0 vol.%, in each case relative to the mobile phase.
- the proportion of organic solvent in the mobile phase may be increased in the course of HPLC separation from 7.5 vol.% to 1 7.5 vol.%, in particular 9.5 to 14.5 vol.%, in each case relative to the mobile phase.
- Eluent A 0.1 M triethylammonium acetate, pH 7
- Eluent B 0.1 M triethylammonium acetate, pH 7, with 25 vol.% acetonitrile
- Eluent composition start: 62% A and 38% B (1 st to 3rd minute) increase to 58% B (1 .67% increase in B per minute), (3rd-15th minute) 100% B (15th to 20th minute)
- purified solvent for HPLC Such purified solvents are commercially obtainable. They may additionally also be filtered with a 1 to 5 ⁇ m microfilter, which is generally mounted in the system upstream of the pump. It is additionally favourable for ail the solvents to be de- gassed prior to use, since otherwise gas bubbles occur in most pumps. If air bubbles occur in the solvent, this may interfere not only with separation but also with the continuous monitoring of outflow in the detector.
- the solvents may be degassed by heating, by vigor- ous stirring with a magnetic stirrer, by brief evacuation, by ultrasonication or by passing a small stream of helium through the solvent storage vessel.
- the flow rate of the eluent is so selected that good separation of the RNA from the other constituents contained in the sample to be investigated takes place.
- the eluent flow rate selected for the method according to the invention may amount to from 1 ml/min to several litres per minute (in the case of upscaling), in particular about 1 to 1000 ml/min, more preferably 5 ml to 500 ml/min, even more preferably more than 100 ml/min, depending on the type and scope of the upscaling. This flow rate may be established and regulated by the pump.
- Detection proceeds favourably with a UV detector at 254 nm, wherein a reference measurement may be made at 600 nm.
- a reference measurement may be made at 600 nm.
- any other detection method may alternatively be used, with which the RNA described above in greater detail may be detected in satisfac- tory and reliable manner.
- RNA-containing eluted solvent quantities For preparative purification of the RNA with the method according to the invention, it is advisable to collect the RNA-containing eluted solvent quantities. In this respect, it is favourable to carry out this collection in such a way that the eluted solvent is collected in individual separated fractions. This may take place for example with a fraction collector. In this way, the high-purity RNA-containing fractions may be separated from other RNA- containing fractions which still contain undesired impurities, albeit in very small quantities. The individual fractions may be collected for example over 1 minute.
- the method according to the invention is favourably performed under completely denaturing conditions. This may proceed for example in that sample application takes place at a temperature of 4-12°C, the HPLC method otherwise proceeding at a higher temperature, preferably at 70 0 C or more, particularly preferably at 75°C or more, in particular up to 82 0 C, and very particularly preferably at about 78°C. Heating is typically important for de- naturing the RNA, whereby better separation is ultimately achieved. Resolution falls at lower temperatures, i.e. separation of the RNA from the impurities decreases. Sample application may be performed with two methods, stop-flow injection or loop injection. For stop-flow injection a microsyringe is used which is able to withstand the high pressure applied in HPLC.
- the sample is injected through a septum in an inlet valve either directly onto the column packing or onto a small drop of inert material immediately over the packing.
- the system may in this case be under elevated pressure, or the pump may be turned off prior to injection, which is then performed when the pressure has fallen to close to the normal value.
- a loop injector is used to introduce the sample. This consists of a tubular loop, into which the sample is inserted.
- the stationary phase is then conveyed out of the pump through the loop, whose outlet leads directly into the column.
- the sample is entrained in this way by the stationary phase into the column, without solvent flow to the pump being interrupted.
- the present invention further provides the use of a porous reversed phase in the above- described HPLC method according to the invention.
- the porous reversed phase has a particle size of 8.0 ⁇ m to 50 ⁇ m, in particular 8.0 to 30, still more preferably 8.0 to 25 ⁇ m.
- the reversed phase may be present in bead form.
- the method according to the invention may be performed particularly favourably with a porous reversed phase with this particle size and/or in the form of beads, wherein particularly good separation results are obtained.
- the reversed phase used for the use according to the invention is porous, since with stationary reversed phases, which are not porous, and thus differ completely with regard to particle size from the subject matter of the present invention, as described for example by A. Azarani and K.H. Hecker, excessively high pressures are built up, such that preparative purification of the RNA by means of HPLC is possible only with great difficulty, if at all.
- the reversed phase has a pore size of 1000 ⁇ to 5000 A, in particular a pore size of 1000 A to 4000 A, or the above-stated preferred values.
- Particularly preferred pore sizes for the reversed phases are 1000-1200 A and 3500-4500 A.
- the material for the reversed phase is a polystyrenedivinylbenzene, wherein in particular non-alkylated polystyrenedivinylbenzene may be used.
- Stationary phases with polystyrenedivinylbenzene are known per se.
- the per se known polystyrenedivinylbenzenes already used for HPLC methods, which are commercially obtainable, may be used for the method according to the invention.
- a non-alkylated porous polystyrenedivinylbenzene which is very particularly preferred for the use according to the invention is one which has in particular a particle size of 8.0 + 1.5 ⁇ m, in particular 8.0 ⁇ 0.5 ⁇ m, and a pore size of 1000- or 4000 A.
- a particle size of 8.0 + 1.5 ⁇ m in particular 8.0 ⁇ 0.5 ⁇ m
- a pore size of 1000- or 4000 A With this material for the reversed phase, the advantages described below may be achieved in a particularly favourable manner.
- this stationary phase described in greater detail above is located in a column.
- V2A steel is conventionally used as the material for the column, but other materials may also be used for the column provided they are suitable for the conditions prevailing during HPLC recovery.
- the column is straight. It is favourable for the HPLC column to have a length of 5 cm to 100 cm and a diameter of 4 mm to 25 mm.
- Columns used for the method according to the invention may in particular have the following dimensions: 50 mm long and 7.5 mm in diameter or 50 mm long and 4.6 mm in diameter, or 50 mm long and 10 mm in diameter or any other dimension with regard to length and diameter, which is suitable for preparative purification of RNA by means of HPLC, even lengths of several metres and also larger diameters being feasible in the case of upscaling.
- the dimensions are here geared towards what is technically possible with liquid chromatography. Further conditions for the use according to the invention have already been described above in connection with the method according to the invention, such that reference is made thereto to avoid unnecessary repetition.
- RNA samples in particular the preferred embodiments described in detail hereinafter, exhibits a series of advantages: in the context of the use according to the invention, substantially larger quantities of RNA may be separated than is possible with the methods known from the prior art.
- the use according to the invention enables these higher quantities to be obtained with a high degree of purity. Separation of degraded fragments or of relatively long fragments or of fragments which have arisen as a result of premature termination of transcription is possible.
- good separation of further impurities present in RNA samples such as enzymes, for example RNases or polymerases, and nucleotides is possible. These relatively large quantities of RNA may be recovered within minutes, even from samples having a very high level of contamination with impurities.
- RNA recovery proceeds reliably, i.e. high purity RNA is recovered with great reliability.
- the use according to the invention enables high resolution to be achieved.
- the use according to the invention may easily be operated automatically. It is thus most suitable for routine purification of RNA on a preparative scale.
- RNA is stable under the conditions of the HPLC separation method, i.e. degradation into RNA fragments and thus the occurrence of new impurities or a reduc- tion in the yield of pure RNA during HPLC purification is avoided.
- Figure 1 shows a chromatogram of a separation of 10 ⁇ g of luciferase-mRNA (analytical);
- Figure 2 shows a chromatogram of a separation of 1 .5 ⁇ g of luciferase-mRNA (preparative);
- Figure 3 shows the chromatogram of Figure 2, the collected fractions being highlighted in grey
- Figure 4 shows verification of the purity of the collected mRNA fractions on an agarose gel
- Figure 5 shows a chromatogram of a separation of 200 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 1000 A;
- Figure 6 shows a chromatogram of a separation of 100 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 4000 A;
- Figure 7 shows a chromatogram of a separation of 250 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary matrix, which has a pore size of 4000 A,
- Figure 8 is a bar chart which demonstrates the improvement in the expression of luciferase from RNA purified with the method according to the invention.
- Figure 9 shows the sequence of the wild-type of luciferase, specifically the mRNA se- quence, which was used for the exemplary embodiments.
- Figure 10 shows a chromatogram of a separation of 3 mg of a Flic(GC) RNA preparation (FC-9050) with a stationary matrix, which has a pore size of 4000 A
- Figure 11 shows a chromatogram of a separation of 1 ,5 mg of a FOLHI (GC) RNA preparation (FO-9334) with a stationary matrix, which has a pore size of 4000 A
- GC FOLHI
- Figure 12 shows a chromatogram of a separation of 1 ,5 mg of a KLK3(GC) RNA preparation (KL-8849) with a stationary matrix, which has a pore size of 4000 A,
- Figure 13 shows a chromatogram of a separation of 1 ,5 mg of a PSCA(GC) RNA preparation (PS-8845) with a stationary matrix, which has a pore size of 4000 A,
- Figure 14 shows a chromatogram of a separation of 1 ,5 mg of a STEAP(GC) RNA preparation (ST-8848) with a stationary matrix, which has a pore size of 4000 A,
- Figure 15 shows a chromatogram of a separation of a mixture of a 2 kb RNA (200 ⁇ g) and a
- Figure 16 shows an agarose gel analysis corresponding to the chromatogram according to
- Figure 15 which shows a separation of a mixture of a 2 kb RNA (200 ⁇ g) and a
- Example 1 Purification of 1 .5 mg of luciferase mRNA by means of the HPLC method according to the invention
- Luciferase mRNA having a size of 1825 base pairs was used for separation.
- a porous, non- alkylated polystyrene/divinylbenzene (polystyrenedivinylbenzene) matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 A.
- the column used was 5.0 cm long and had a diameter of 7.5 mm.
- the sampler temperature was 12°C
- the temperature for the HPLC separation, in particular of the separation column was 78°C, i.e. operations were carried out under completely denaturing conditions.
- Eluent B 0.1 M triethylammonium acetate, pH 7, with 25 vol.% acetonitrile Eluent composition: start: 62% A and 38% B (1 st to 3rd minute) increase to 58% B (1 .67% increase in B per minute), (3rd-15th minute) 100% B (15th to 20th minute)
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
- the purpose of purifying the luciferase mRNA on a preparative scale is to remove these undesired impurities.
- Figures 2 and 3 show the corresponding chromatograms for the separation of luciferase mRNA on a preparative scale (1 .5 mg), wherein the gradient program is shown in broken lines in Figure 2.
- the collected fractions 1 to 10 are highlighted in grey in Figures 2 and 3; the fractions were collected over a period of 1 minute.
- This exemplary embodiment shows that, using the method according to the invention, it is possible to purify mRNA on a preparative scale by means of HPLC.
- Example 2 Separation of 200 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 1000 A;
- RNA fragments 200 ⁇ g of a 2 kb and 4 kb RNA fragment were used for separation.
- a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 1000 ⁇ .
- the column used was 2.5 cm long and had a diameter of 4.6 mm.
- the sampler temperature was 12°C
- the temperature for the HPLC separation, in particular of the separa- tion column was 78°C, i.e. operations were carried out under completely denaturing conditions.
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
- Figure 5 shows the corresponding chromatograms for this separation on a preparative scale (200 ⁇ g), wherein the gradient program is shown in broken lines in Figure 5.
- the collected fractions are highlighted in grey in Figure 5; the fractions were collected over a period of 1 minute.
- a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
- Example 3 Separation of 100 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 4000 A;
- RNA fragment 100 ⁇ g of a 2 kb and 4 kb RNA fragment were used for separation.
- a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 A.
- the column used was 2.5 cm long and had a diameter of 4.6 mm.
- the sampler temperature was 12°C
- the temperature for the HPLC separation, in particular of the separa- tion column was 78°C, i.e. operations were carried out under completely denaturing conditions.
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
- Figure 6 shows the corresponding chromatograms for this separation on a preparative scale (100 ⁇ g), wherein the gradient program is shown in broken lines in Figure 6. The fractions collected are highlighted in grey in Figure 6. As a result, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
- Example 4 Separation of 250 ⁇ g of a 2 kb and of a 4 kb RNA fragment with a stationary phase, which has a pore size of 4000 A;
- RNA fragments 250 ⁇ g of a 2 kb and 4 kb RNA fragment were used for separation.
- a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 A.
- the column used was 2.5 cm long and had a diameter of 4.6 mm.
- the sampler temperature was 12 0 C
- the temperature for the HPLC separation, in particular of the separation column was 78 0 C, i.e. operations were carried out under completely denaturing con- ditions.
- Eluent B 0.1 M triethylammonium acetate/25% acetonitri Ie Eluent composition: starting level: 62% A and 38% B (1 st-3rd min) separation range I: gradient 38%-49.5% B (5.75% increase in B/min) (3rd-
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/mi n.
- Figure 7 shows the corresponding chromatograms for this separation on a preparative scale (250 ⁇ g), wherein the gradient program is shown in broken lines in Figure 7. The fractions collected are highlighted in grey in Figure 7. As a result, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
- Example 5 Separation of 3 mg of a 1,7 kb RNA (FliC(GC)-preparation, FC9050) with a stationary phase, which has a pore size of 4000 A;
- RNA 1 ,7 kb RNA
- FC9050 1 ,7 kb RNA
- a porous, non-alkylated polystyrene/divinylbenzene matrix (conventional commercial product from Polymer Laboratories) was used as the stationary phase. It had a particle size of 8 ⁇ m and a pore size of 4000 A.
- the column used was 2.5 cm long and had a diameter of 4.6 mm.
- the sampler temperature was 12°C
- the temperature for the HPLC separation, in particular of the separation column was 78°C, i.e. operations were carried out under completely denaturing conditions.
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
- Figure 10 shows the corresponding chromatograms for this separation on a preparative scale (3 mg), wherein the gradient program is shown in broken lines in Figure 10. The fractions collected are highlighted in grey in Figure 10. As can be seen, a separation of the RNA was successful, leading to a highly pure fraction of RNA in preparative scale.
- Example 6 Separation of 1,5 mg of a FOLHI (GC) RNA preparation (FO-9334), 1 ,5 mg of a KLK3(GC) RNA preparation (KL-8849), 1,5 mg of a PSCA(GC) RNA preparation (PS-8845) or 1 ,5 mg of a STEAP(GC) RNA preparation (ST-8848) with a stationary phase, which has a pore size of 4000 A;
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
- Figures 1 1 , 12, 13 and 14 shows the corresponding chromatograms for this separation of 1 ,5 mg of a FOLHI (GC) RNA preparation (FO-9334), 1 ,5 mg of a KLK3(GC) RNA preparation (KL-8849), 1 ,5 mg of a PSCA(GC) RNA preparation (PS-8845) or 1 ,5 mg of a STEAP(GC) RNA preparation (ST-8848), respectively on a preparative scale (1 ,5 mg), wherein the gradient program is shown in broken lines in these Figures.
- the fractions collected are high- lighted in grey in Figure 1 1 , 12, 13 and 14. As can be seen, a separation of the RNAs is possible in each case, leading to a highly pure fraction of RNA in each case in preparative scale.
- Example 7 Separation of a mixture of 200 ⁇ g of a 2 kb RNA and 200 ⁇ g of a 4kb RNA on a non-porous stationary polystyrenedivinylbenzene matrix (Comparison Example)
- a mixture of 200 ⁇ g of a 2 kb RNA and 200 ⁇ g of a 4kb RNA were used for separation.
- the columns used were packed with either a 1000 ⁇ non-alkylated porous polystyrenedivinyl- benzene or a non-porous stationary polystyrenedivinylbenzene matrix.
- the column used for the 1000 A non-alkylated porous polystyrenedivinylbenzene was 2.5 cm long and had a diameter of 4.6 mm.
- the column used for the non-alkylated non-porous polystyrenedivinylbenzene was 2.5 cm long and had a diameter of 4.0 mm.
- the sampler temperature was 12°C
- the temperature for the HPLC separation, in particular of the separation column was 78°C, i.e. operations were carried out under completely denaturing conditions.
- Detection proceeded with a UV detector at 254 nm with a reference measurement at 600 nm. Flow rate was 3 ml/min.
- Figures 15 shows the corresponding chromatogram for this separation on a preparative scale (each 200 ⁇ g), wherein the gradient program is shown in broken lines in Figure 15. The fractions collected are highlighted in grey in Figure 15. As can be seen, a separation of both RNAs is not possible using a common non-alkylated porous polystyrenedivinylbenzene as a matrix.
- Figure 16 shows the agarose gel corresponding to the chromatogram according to Figure 15.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2670727A CA2670727C (en) | 2006-12-22 | 2007-12-20 | Method for purifying rna on a preparative scale by means of hplc |
PL07857017T PL2092064T3 (en) | 2006-12-22 | 2007-12-20 | Method for purifying rna on a preparative scale by means of hplc |
AU2007338360A AU2007338360B2 (en) | 2006-12-22 | 2007-12-20 | Method for purifying RNA on a preparative scale by means of HPLC |
JP2009541898A JP5307724B2 (en) | 2006-12-22 | 2007-12-20 | Method of purifying RNA using HPLC on a preparative scale |
DK07857017.3T DK2092064T3 (en) | 2006-12-22 | 2007-12-20 | Method of Preparative RNA Purification by HPLC |
DE602007009295T DE602007009295D1 (en) | 2006-12-22 | 2007-12-20 | PROCESS FOR PREPARANT RNA CLEANING BY HPLC |
KR1020097012957A KR101183173B1 (en) | 2006-12-22 | 2007-12-20 | Method for purifying rna on a preparative scale by means of hplc |
EP07857017A EP2092064B1 (en) | 2006-12-22 | 2007-12-20 | Method for purifying rna on a preparative scale by means of hplc |
CN200780047133.2A CN101563457B (en) | 2006-12-22 | 2007-12-20 | Method for purifying RNA on preparative scale by means of HPLC |
AT07857017T ATE481482T1 (en) | 2006-12-22 | 2007-12-20 | METHOD FOR PRELIMINARY RNA PURIFICATION USING HPLC |
US12/520,172 US8383340B2 (en) | 2006-12-22 | 2007-12-20 | Method for purifying RNA on a preparative scale by means of HPLC |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006061015A DE102006061015A1 (en) | 2006-12-22 | 2006-12-22 | Process for the purification of RNA on a preparative scale by HPLC |
DE102006061015.6 | 2006-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008077592A1 true WO2008077592A1 (en) | 2008-07-03 |
Family
ID=39186980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/011294 WO2008077592A1 (en) | 2006-12-22 | 2007-12-20 | Method for purifying rna on a preparative scale by means of hplc |
Country Status (13)
Country | Link |
---|---|
US (1) | US8383340B2 (en) |
EP (1) | EP2092064B1 (en) |
JP (1) | JP5307724B2 (en) |
KR (1) | KR101183173B1 (en) |
CN (1) | CN101563457B (en) |
AT (1) | ATE481482T1 (en) |
AU (1) | AU2007338360B2 (en) |
CA (1) | CA2670727C (en) |
DE (2) | DE102006061015A1 (en) |
DK (1) | DK2092064T3 (en) |
ES (1) | ES2352306T3 (en) |
PL (1) | PL2092064T3 (en) |
WO (1) | WO2008077592A1 (en) |
Cited By (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014140211A1 (en) | 2013-03-15 | 2014-09-18 | Novartis Ag | Rna purification methods |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
WO2015188933A1 (en) | 2014-06-10 | 2015-12-17 | Curevac Ag | Methods and means for enhancing rna production |
US9352028B2 (en) | 2007-10-09 | 2016-05-31 | Curevac Ag | Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC) |
US9402887B2 (en) | 2007-10-09 | 2016-08-02 | Curevac Ag | Composition for treating prostate cancer (PCa) |
WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2017001058A1 (en) * | 2015-07-01 | 2017-01-05 | Curevac Ag | Method for analysis of an rna molecule |
WO2017049245A2 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US9616084B2 (en) | 2009-12-09 | 2017-04-11 | Curevac Ag | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
WO2017066793A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
WO2017112865A1 (en) | 2015-12-22 | 2017-06-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018033254A2 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
WO2018041921A1 (en) | 2016-08-31 | 2018-03-08 | Curevac Ag | Mixing device for the production of a liquid nucleic acid composition |
WO2018078053A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
WO2018141371A1 (en) | 2017-01-31 | 2018-08-09 | Curevac Ag | Purification and/or formulation of rna |
WO2018170306A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2018167320A1 (en) | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2018211038A1 (en) | 2017-05-17 | 2018-11-22 | Curevac Ag | Method for determining at least one quality parameter of an rna sample |
WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
EP3424524A2 (en) | 2017-07-04 | 2019-01-09 | CureVac AG | Cancer rna-vaccine |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Methods of preparing modified rna |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
EP3450561A1 (en) | 2013-08-21 | 2019-03-06 | CureVac AG | Method for increasing expression of rna-encoded proteins |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
EP3461498A1 (en) | 2013-08-21 | 2019-04-03 | CureVac AG | Rabies vaccine |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
EP3542802A1 (en) | 2013-11-01 | 2019-09-25 | CureVac AG | Modified rna with decreased immunostimulatory properties |
WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
EP3586871A2 (en) | 2013-08-21 | 2020-01-01 | CureVac AG | Respiratory syncytial virus (rsv) vaccine |
WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
US10653712B2 (en) | 2016-09-14 | 2020-05-19 | Modernatx, Inc. | High purity RNA compositions and methods for preparation thereof |
WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
WO2020160430A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Vortex mixers and associated methods, systems, and apparatuses thereof |
WO2020160397A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
WO2021123332A1 (en) | 2019-12-20 | 2021-06-24 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
WO2021156267A1 (en) | 2020-02-04 | 2021-08-12 | Curevac Ag | Coronavirus vaccine |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
WO2021204175A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
EP3916091A2 (en) | 2015-05-20 | 2021-12-01 | CureVac AG | Dry powder composition comprising long-chain rna |
WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
WO2021254593A1 (en) | 2020-06-15 | 2021-12-23 | Curevac Ag | Analysis of nucleic acid mixtures |
EP3928800A2 (en) | 2015-05-20 | 2021-12-29 | CureVac AG | Dry powder composition comprising long-chain rna |
WO2022002040A1 (en) | 2020-06-30 | 2022-01-06 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
WO2022037652A1 (en) | 2020-08-20 | 2022-02-24 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
WO2022049093A1 (en) | 2020-09-01 | 2022-03-10 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
WO2022112498A1 (en) | 2020-11-27 | 2022-06-02 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022200575A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
WO2022240960A1 (en) * | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
WO2022247755A1 (en) | 2021-05-24 | 2022-12-01 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
WO2023044333A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
EP4162950A1 (en) | 2021-10-08 | 2023-04-12 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
WO2023056914A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023056917A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023116804A1 (en) | 2021-12-23 | 2023-06-29 | 苏州艾博生物科技有限公司 | Lipid compound and lipid nanoparticle composition |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
EP4227319A1 (en) | 2018-04-17 | 2023-08-16 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
EP4289965A2 (en) | 2016-02-12 | 2023-12-13 | CureVac SE | Method for analyzing rna |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
US11872280B2 (en) | 2020-12-22 | 2024-01-16 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
EP4353257A2 (en) | 2015-04-13 | 2024-04-17 | CureVac Manufacturing GmbH | Method for producing rna compositions |
US11964011B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
WO2024160895A1 (en) | 2023-01-31 | 2024-08-08 | CureVac SE | Cap analogs with 5'-terminal acyclic guanosine derivative |
WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
WO2024171052A1 (en) | 2023-02-14 | 2024-08-22 | Glaxosmithkline Biologicals Sa | Analytical method |
WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
WO2024192277A2 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
US12109275B2 (en) | 2010-08-13 | 2024-10-08 | CureVac SE | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007001370A1 (en) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2010033652A1 (en) * | 2008-09-17 | 2010-03-25 | Ge Healthcare Bio-Sciences Corp. | Method for small rna isolation |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HRP20220796T1 (en) | 2010-10-01 | 2022-10-14 | ModernaTX, Inc. | Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
RS63244B1 (en) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Modified mrna compositions |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
RU2658490C2 (en) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Artificial nucleic acid molecules for improved protein or peptide expression |
BR112014023800A2 (en) | 2012-03-27 | 2017-07-18 | Curevac Gmbh | artificial nucleic acid molecules |
CA2866945C (en) | 2012-03-27 | 2021-05-04 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
PL2922554T3 (en) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Terminally modified rna |
SG10201710473VA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
JP2016514970A (en) | 2013-03-14 | 2016-05-26 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | Quantitative evaluation of messenger RNA cap efficiency |
WO2014144711A1 (en) * | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US11377470B2 (en) * | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
US9822378B2 (en) | 2013-05-15 | 2017-11-21 | Ribokine, Llc | Intracellular translation of circular RNA |
EP3019619B1 (en) | 2013-07-11 | 2021-08-25 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
BR112016001192A2 (en) | 2013-08-21 | 2017-08-29 | Curevac Ag | VACCINE AGAINST ANGER |
CA2915724C (en) | 2013-08-21 | 2023-09-26 | Patrick Baumhof | Method for increasing expression of rna-encoded proteins |
CN105473157A (en) | 2013-08-21 | 2016-04-06 | 库瑞瓦格股份公司 | Combination vaccine |
KR20160044566A (en) | 2013-08-21 | 2016-04-25 | 큐어백 아게 | Respiratory syncytial virus (RSV) vaccine |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
JP6584414B2 (en) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | Artificial nucleic acid molecule |
CA2927862C (en) | 2013-12-30 | 2024-01-23 | Curevac Ag | Artificial nucleic acid molecules |
ES2754239T3 (en) | 2014-03-12 | 2020-04-16 | Curevac Ag | Combination of vaccination and OX40 agonists |
BR112016024644A2 (en) | 2014-04-23 | 2017-10-10 | Modernatx Inc | nucleic acid vaccines |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
JP2017522028A (en) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Circular polynucleotide |
EP3230458B1 (en) | 2014-12-12 | 2020-02-19 | CureVac AG | Artificial nucleic acid molecules for improved protein expression |
WO2016165831A1 (en) | 2015-04-17 | 2016-10-20 | Curevac Ag | Lyophilization of rna |
EP3289101B1 (en) | 2015-04-30 | 2021-06-23 | CureVac AG | Immobilized poly(n)polymerase |
US11608513B2 (en) | 2015-05-29 | 2023-03-21 | CureVac SE | Method for adding cap structures to RNA using immobilized enzymes |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
AU2016324463B2 (en) | 2015-09-17 | 2022-10-27 | Modernatx, Inc. | Polynucleotides containing a stabilizing tail region |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
WO2017064146A1 (en) | 2015-10-12 | 2017-04-20 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017081110A1 (en) | 2015-11-09 | 2017-05-18 | Curevac Ag | Rotavirus vaccines |
WO2017140905A1 (en) | 2016-02-17 | 2017-08-24 | Curevac Ag | Zika virus vaccine |
PL3445850T3 (en) | 2016-04-22 | 2022-01-17 | BioNTech SE | Methods for providing single-stranded rna |
EP3448427A1 (en) | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
EP3808380A1 (en) | 2016-12-08 | 2021-04-21 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
BR112019015244A2 (en) | 2017-03-24 | 2020-04-14 | Curevac Ag | nucleic acids encoding proteins associated with crispr and uses thereof |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
US10034951B1 (en) | 2017-06-21 | 2018-07-31 | New England Biolabs, Inc. | Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity |
US11525158B2 (en) | 2017-12-21 | 2022-12-13 | CureVac SE | Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA |
CN113166737A (en) | 2018-10-04 | 2021-07-23 | 新英格兰生物实验室公司 | Methods and compositions for increasing the efficiency of capping of transcribed RNA |
US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
AU2020337069A1 (en) | 2019-08-28 | 2022-04-14 | Contamination Source Identification Llc | Rapid isolation and collection of microbial RNA from a biological specimen |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
WO2021195212A1 (en) * | 2020-03-25 | 2021-09-30 | Waters Technologies Corporation | Devices and methods for the sensitive detection and quantitation of biomolecules |
US11028379B1 (en) | 2021-01-27 | 2021-06-08 | New England Biolabs, Inc. | FCE mRNA capping enzyme compositions, methods and kits |
AU2021424650A1 (en) | 2021-01-27 | 2023-08-17 | New England Biolabs, Inc. | Faustovirus capping enzyme, mrna capping enzyme compositions, methods and kits |
JP2024520636A (en) | 2021-06-04 | 2024-05-24 | トランスレイト バイオ, インコーポレイテッド | Assay for quantitative evaluation of mRNA capping efficiency |
WO2023014649A1 (en) | 2021-08-02 | 2023-02-09 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment |
KR102646914B1 (en) * | 2021-10-01 | 2024-03-12 | 서울대학교산학협력단 | Direct and simultaneous analysis of all oleoylglycerol isomers and oleic acid and determination of lipase stereoselectivity thereof |
WO2023196950A1 (en) | 2022-04-07 | 2023-10-12 | New England Biolabs, Inc. | Methods of higher fidelity rna synthesis |
WO2024030369A1 (en) | 2022-08-01 | 2024-02-08 | Modernatx, Inc. | Extraction-less reverse phase (rp) chromatography for mrna purity assessment |
CN115774075B (en) * | 2023-02-15 | 2023-06-06 | 江苏耀海生物制药有限公司 | Method for analyzing in vitro transcription product component circRNA based on RP-HPLC |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2468048A1 (en) * | 1994-02-23 | 1995-08-31 | Pamela Pavco | Process for purifying chemically synthesized rna |
US20020102563A1 (en) * | 1998-04-24 | 2002-08-01 | Gjerde Douglas T. | Apparatus and method for separating and purifying polynucleotides |
US20050011836A1 (en) * | 2003-07-17 | 2005-01-20 | Brian Bidlingmeyer | Additives for reversed-phase HPLC mobile phases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447922A (en) | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
EP1331976A2 (en) * | 1999-12-22 | 2003-08-06 | TRANSGENOMIC, Inc. | System and method for automated matched ion polynucleotide chromatography |
US7655790B2 (en) * | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
US7781573B2 (en) * | 2006-08-03 | 2010-08-24 | Nam Q Ngo | Multi layer chromatography of nucleic acids |
DE102007001370A1 (en) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-encoded antibodies |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
-
2006
- 2006-12-22 DE DE102006061015A patent/DE102006061015A1/en not_active Ceased
-
2007
- 2007-12-20 JP JP2009541898A patent/JP5307724B2/en active Active
- 2007-12-20 AU AU2007338360A patent/AU2007338360B2/en active Active
- 2007-12-20 CN CN200780047133.2A patent/CN101563457B/en active Active
- 2007-12-20 PL PL07857017T patent/PL2092064T3/en unknown
- 2007-12-20 WO PCT/EP2007/011294 patent/WO2008077592A1/en active Application Filing
- 2007-12-20 EP EP07857017A patent/EP2092064B1/en active Active
- 2007-12-20 ES ES07857017T patent/ES2352306T3/en active Active
- 2007-12-20 KR KR1020097012957A patent/KR101183173B1/en active IP Right Grant
- 2007-12-20 DK DK07857017.3T patent/DK2092064T3/en active
- 2007-12-20 AT AT07857017T patent/ATE481482T1/en active
- 2007-12-20 US US12/520,172 patent/US8383340B2/en active Active
- 2007-12-20 CA CA2670727A patent/CA2670727C/en active Active
- 2007-12-20 DE DE602007009295T patent/DE602007009295D1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2468048A1 (en) * | 1994-02-23 | 1995-08-31 | Pamela Pavco | Process for purifying chemically synthesized rna |
US20020102563A1 (en) * | 1998-04-24 | 2002-08-01 | Gjerde Douglas T. | Apparatus and method for separating and purifying polynucleotides |
US20050011836A1 (en) * | 2003-07-17 | 2005-01-20 | Brian Bidlingmeyer | Additives for reversed-phase HPLC mobile phases |
Non-Patent Citations (3)
Title |
---|
ANDERSON AMY C ET AL: "HPLC purification of RNA for crystallography and NMR", RNA (NEW YORK), vol. 2, no. 2, 1996, pages 110 - 117, XP002474348, ISSN: 1355-8382 * |
AZARANI A ET AL: "RNA analysis by ion-pair reversed-phase high performance liquid chromatography.", NUCLEIC ACIDS RESEARCH 15 JAN 2001, vol. 29, no. 2, 15 January 2001 (2001-01-15), pages E7, XP002474349, ISSN: 1362-4962 * |
DICKMAN MARK J ET AL: "Enrichment and analysis of RNA centered on ion pair reverse phase methodology", RNA (COLD SPRING HARBOR), vol. 12, no. 4, April 2006 (2006-04-01), pages 691 - 696, XP002474347, ISSN: 1355-8382 * |
Cited By (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10434154B2 (en) | 2007-10-09 | 2019-10-08 | Curevac Ag | Composition for treating prostate cancer (PCa) |
US12048738B2 (en) | 2007-10-09 | 2024-07-30 | CureVac SE | Composition for treating prostate cancer (PCa) |
US9352028B2 (en) | 2007-10-09 | 2016-05-31 | Curevac Ag | Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC) |
US9402887B2 (en) | 2007-10-09 | 2016-08-02 | Curevac Ag | Composition for treating prostate cancer (PCa) |
US9616084B2 (en) | 2009-12-09 | 2017-04-11 | Curevac Ag | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
US12109275B2 (en) | 2010-08-13 | 2024-10-08 | CureVac SE | Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
US10751386B2 (en) | 2011-09-12 | 2020-08-25 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
US10022425B2 (en) | 2011-09-12 | 2018-07-17 | Modernatx, Inc. | Engineered nucleic acids and methods of use thereof |
EP3521429A1 (en) | 2013-03-15 | 2019-08-07 | GlaxoSmithKline Biologicals SA | Rna purification methods |
WO2014140211A1 (en) | 2013-03-15 | 2014-09-18 | Novartis Ag | Rna purification methods |
EP4043032A1 (en) | 2013-08-21 | 2022-08-17 | CureVac AG | Rabies vaccine |
EP3461498A1 (en) | 2013-08-21 | 2019-04-03 | CureVac AG | Rabies vaccine |
EP3586871A2 (en) | 2013-08-21 | 2020-01-01 | CureVac AG | Respiratory syncytial virus (rsv) vaccine |
EP3450561A1 (en) | 2013-08-21 | 2019-03-06 | CureVac AG | Method for increasing expression of rna-encoded proteins |
US10815291B2 (en) | 2013-09-30 | 2020-10-27 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
EP3542802A1 (en) | 2013-11-01 | 2019-09-25 | CureVac AG | Modified rna with decreased immunostimulatory properties |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
EP3540060A1 (en) | 2013-12-30 | 2019-09-18 | CureVac AG | Methods for rna analysis |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
US10648017B2 (en) | 2013-12-30 | 2020-05-12 | Curevac Real Estate Gmbh | Methods for RNA analysis |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
EP3521456A1 (en) | 2014-06-10 | 2019-08-07 | CureVac AG | Methods and means for enhancing rna production |
WO2015188933A1 (en) | 2014-06-10 | 2015-12-17 | Curevac Ag | Methods and means for enhancing rna production |
EP4353257A2 (en) | 2015-04-13 | 2024-04-17 | CureVac Manufacturing GmbH | Method for producing rna compositions |
EP3326641A1 (en) | 2015-04-22 | 2018-05-30 | CureVac AG | Rna containing composition for treatment of tumor diseases |
EP3173092A2 (en) | 2015-04-22 | 2017-05-31 | CureVac AG | Rna containing composition for treatment of tumor diseases |
EP3603661A2 (en) | 2015-04-22 | 2020-02-05 | CureVac AG | Rna containing composition for treatment of tumor diseases |
WO2016170176A1 (en) | 2015-04-22 | 2016-10-27 | Curevac Ag | Rna containing composition for treatment of tumor diseases |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
EP3928800A2 (en) | 2015-05-20 | 2021-12-29 | CureVac AG | Dry powder composition comprising long-chain rna |
EP3916091A2 (en) | 2015-05-20 | 2021-12-01 | CureVac AG | Dry powder composition comprising long-chain rna |
DE202016009003U1 (en) | 2015-05-29 | 2021-05-28 | Curevac Real Estate Gmbh | Composition comprising in vitro transcribed RNA obtainable by a method for the production and purification of RNA with at least one step with a tangential flow filtration |
EP4108769A1 (en) | 2015-05-29 | 2022-12-28 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
US11834651B2 (en) | 2015-05-29 | 2023-12-05 | CureVac Manufacturing GmbH | Method for producing and purifying RNA, comprising at least one step of tangential flow filtration |
EP3744843A1 (en) | 2015-05-29 | 2020-12-02 | CureVac Real Estate GmbH | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
EP4239080A2 (en) | 2015-07-01 | 2023-09-06 | CureVac Manufacturing GmbH | Method for analysis of an rna molecule |
WO2017001058A1 (en) * | 2015-07-01 | 2017-01-05 | Curevac Ag | Method for analysis of an rna molecule |
EP3736261A1 (en) | 2015-09-17 | 2020-11-11 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2017049245A2 (en) | 2015-09-17 | 2017-03-23 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP4286012A2 (en) | 2015-09-17 | 2023-12-06 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
EP4086269A1 (en) | 2015-10-16 | 2022-11-09 | ModernaTX, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
WO2017066793A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs and methods of mrna capping |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
EP4036079A2 (en) | 2015-12-22 | 2022-08-03 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2017112865A1 (en) | 2015-12-22 | 2017-06-29 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
EP3701963A1 (en) | 2015-12-22 | 2020-09-02 | CureVac AG | Method for producing rna molecule compositions |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
WO2017109161A1 (en) | 2015-12-23 | 2017-06-29 | Curevac Ag | Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
EP4289965A2 (en) | 2016-02-12 | 2023-12-13 | CureVac SE | Method for analyzing rna |
WO2017140345A1 (en) | 2016-02-15 | 2017-08-24 | Curevac Ag | Method for analyzing by-products of rna in vitro transcription |
WO2017149139A1 (en) | 2016-03-03 | 2017-09-08 | Curevac Ag | Rna analysis by total hydrolysis |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
WO2017191264A1 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Nucleic acid molecules and uses thereof |
WO2017212006A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
WO2017212009A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Hybrid carriers for nucleic acid cargo |
WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018033254A2 (en) | 2016-08-19 | 2018-02-22 | Curevac Ag | Rna for cancer therapy |
WO2018041921A1 (en) | 2016-08-31 | 2018-03-08 | Curevac Ag | Mixing device for the production of a liquid nucleic acid composition |
US11202793B2 (en) | 2016-09-14 | 2021-12-21 | Modernatx, Inc. | High purity RNA compositions and methods for preparation thereof |
US10653712B2 (en) | 2016-09-14 | 2020-05-19 | Modernatx, Inc. | High purity RNA compositions and methods for preparation thereof |
WO2018078053A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
US11279923B2 (en) | 2016-11-28 | 2022-03-22 | Curevac Ag | Method for purifying RNA |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
WO2018115527A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
WO2018115525A1 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Lassa virus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
WO2018141371A1 (en) | 2017-01-31 | 2018-08-09 | Curevac Ag | Purification and/or formulation of rna |
EP4186888A1 (en) | 2017-03-15 | 2023-05-31 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
WO2018170306A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2018170336A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
WO2018167320A1 (en) | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
WO2018211038A1 (en) | 2017-05-17 | 2018-11-22 | Curevac Ag | Method for determining at least one quality parameter of an rna sample |
WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | Novel nucleic acid molecules |
EP3424524A2 (en) | 2017-07-04 | 2019-01-09 | CureVac AG | Cancer rna-vaccine |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | Methods of preparing modified rna |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
US11912982B2 (en) | 2017-08-18 | 2024-02-27 | Modernatx, Inc. | Methods for HPLC analysis |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
EP4227319A1 (en) | 2018-04-17 | 2023-08-16 | CureVac SE | Novel rsv rna molecules and compositions for vaccination |
WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
EP4273266A2 (en) | 2018-06-28 | 2023-11-08 | CureVac RNA Printer GmbH | Bioreactor for rna in vitro transcription |
WO2020002598A1 (en) | 2018-06-28 | 2020-01-02 | Curevac Ag | Bioreactor for rna in vitro transcription |
WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
WO2020128031A2 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
EP4427739A2 (en) | 2019-01-31 | 2024-09-11 | ModernaTX, Inc. | Methods of preparing lipid nanoparticles |
WO2020160397A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020160430A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Vortex mixers and associated methods, systems, and apparatuses thereof |
WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
WO2020254535A1 (en) | 2019-06-18 | 2020-12-24 | Curevac Ag | Rotavirus mrna vaccine |
WO2021028439A1 (en) | 2019-08-14 | 2021-02-18 | Curevac Ag | Rna combinations and compositions with decreased immunostimulatory properties |
WO2021123332A1 (en) | 2019-12-20 | 2021-06-24 | Curevac Ag | Lipid nanoparticles for delivery of nucleic acids |
DE112021000012T5 (en) | 2020-02-04 | 2021-11-18 | Curevac Ag | Coronavirus vaccine |
DE202021004130U1 (en) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus Vaccine |
DE202021004123U1 (en) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus Vaccine |
DE202021003575U1 (en) | 2020-02-04 | 2022-01-17 | Curevac Ag | Coronavirus Vaccine |
WO2021156267A1 (en) | 2020-02-04 | 2021-08-12 | Curevac Ag | Coronavirus vaccine |
US11964012B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
US11964011B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
EP4147717A1 (en) | 2020-02-04 | 2023-03-15 | CureVac SE | Coronavirus vaccine |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
WO2021204175A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
WO2021239880A1 (en) | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
WO2021254593A1 (en) | 2020-06-15 | 2021-12-23 | Curevac Ag | Analysis of nucleic acid mixtures |
WO2022002040A1 (en) | 2020-06-30 | 2022-01-06 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
WO2022037652A1 (en) | 2020-08-20 | 2022-02-24 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022043551A2 (en) | 2020-08-31 | 2022-03-03 | Curevac Ag | Multivalent nucleic acid based coronavirus vaccines |
WO2022049093A1 (en) | 2020-09-01 | 2022-03-10 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
WO2022112498A1 (en) | 2020-11-27 | 2022-06-02 | CureVac RNA Printer GmbH | A device for preparing a dna product by means of capillary polymerase chain reaction |
WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
US11872280B2 (en) | 2020-12-22 | 2024-01-16 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
WO2022200575A1 (en) | 2021-03-26 | 2022-09-29 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
WO2022240960A1 (en) * | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
WO2022247755A1 (en) | 2021-05-24 | 2022-12-01 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
WO2023007019A1 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
WO2023044333A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
WO2023056917A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023056914A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
EP4162950A1 (en) | 2021-10-08 | 2023-04-12 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023116804A1 (en) | 2021-12-23 | 2023-06-29 | 苏州艾博生物科技有限公司 | Lipid compound and lipid nanoparticle composition |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2024030856A2 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024068545A1 (en) | 2022-09-26 | 2024-04-04 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
DE202023106198U1 (en) | 2022-10-28 | 2024-03-21 | CureVac SE | Nucleic acid-based vaccine |
WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2024160895A1 (en) | 2023-01-31 | 2024-08-08 | CureVac SE | Cap analogs with 5'-terminal acyclic guanosine derivative |
WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
WO2024171052A1 (en) | 2023-02-14 | 2024-08-22 | Glaxosmithkline Biologicals Sa | Analytical method |
WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
WO2024192277A2 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
Also Published As
Publication number | Publication date |
---|---|
KR101183173B1 (en) | 2012-09-14 |
DK2092064T3 (en) | 2010-12-13 |
CA2670727A1 (en) | 2008-07-03 |
DE102006061015A1 (en) | 2008-06-26 |
JP2010512767A (en) | 2010-04-30 |
EP2092064B1 (en) | 2010-09-15 |
CA2670727C (en) | 2012-10-09 |
ES2352306T3 (en) | 2011-02-17 |
AU2007338360A1 (en) | 2008-07-03 |
EP2092064A1 (en) | 2009-08-26 |
US20100048883A1 (en) | 2010-02-25 |
CN101563457A (en) | 2009-10-21 |
PL2092064T3 (en) | 2011-03-31 |
ATE481482T1 (en) | 2010-10-15 |
AU2007338360B2 (en) | 2011-06-02 |
DE602007009295D1 (en) | 2010-10-28 |
KR20090098968A (en) | 2009-09-18 |
US8383340B2 (en) | 2013-02-26 |
JP5307724B2 (en) | 2013-10-02 |
CN101563457B (en) | 2014-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8383340B2 (en) | Method for purifying RNA on a preparative scale by means of HPLC | |
Eon-Duval et al. | Purification of pharmaceutical-grade plasmid DNA by anion-exchange chromatography in an RNase-free process | |
Tian et al. | Evaluation of silica resins for direct and efficient extraction of DNA from complex biological matrices in a miniaturized format | |
US7510826B2 (en) | Process for the depletion or removal of endotoxins | |
JP2005137295A (en) | Method for extracting rna, and method for analyzing biomaterial | |
Hanora et al. | Direct capture of plasmid DNA from non-clarified bacterial lysate using polycation-grafted monoliths | |
JPH09508283A (en) | Enhanced transfection efficiency of nucleic acids using isopropanol-containing aqueous solution | |
CA2245576C (en) | Process for preparing purified nucleic acid and the use thereof | |
Santos et al. | Influenza DNA vaccine purification using pHEMA cryogel support | |
Yih-Fen et al. | Rapid high-performance liquid chromatography of nucleic acids with polystyrene-based micropellicular anion exchangers | |
Krajnc et al. | Purification of large plasmids with methacrylate monolithic columns | |
Andrus et al. | Analysis and purification of synthetic nucleic acids using HPLC | |
Bonturi et al. | Sodium citrate and potassium phosphate as alternative adsorption buffers in hydrophobic and aromatic thiophilic chromatographic purification of plasmid DNA from neutralized lysate | |
Bicho et al. | Application of ethylenediamine monolith to purify a hemagglutinin influenza deoxyribonucleic acid-based vaccine | |
Corradini et al. | Combined lectin-affinity and metal-interaction chromatography for the separation of glycophorins by high-performance liquid chromatography | |
AU2003206358B2 (en) | Method of separation using aromatic thioether ligands | |
JP4125605B2 (en) | Purification of plasmid DNA with hydroxyapatite without acetic acid | |
JP2007519407A (en) | Method for chromatographic separation of nucleic acid mixtures | |
Zhong et al. | Developing an RNase-free bioprocess to produce pharmaceutical-grade plasmid DNA using selective precipitation and membrane chromatography | |
US20090047734A1 (en) | Method of separation of deoxyribonucleic acids | |
Ebrahimpour et al. | Adsorption strategy of plasmid DNA nanoparticulate: Preparative purification by a simple custom expanded bed column | |
Tseng et al. | Effect of alcohol on purification of plasmid DNA using ion-exchange membrane | |
EP1578968A1 (en) | Isolation of antisense oligonucleotides | |
JP4073429B2 (en) | Reagent for RNA extraction | |
JP5948425B2 (en) | Separation of acetylated protein from non-acetylated protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780047133.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07857017 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007857017 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2670727 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3565/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007338360 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009541898 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097012957 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007338360 Country of ref document: AU Date of ref document: 20071220 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12520172 Country of ref document: US |